Free Trial

Cybin (CYBN) Competitors

Cybin logo
$7.97 -0.07 (-0.87%)
As of 03:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CYBN vs. MRVI, IOVA, URGN, TLRY, TNGX, STOK, PRME, DNTH, PHAT, and UPB

Should you be buying Cybin stock or one of its competitors? The main competitors of Cybin include Maravai LifeSciences (MRVI), Iovance Biotherapeutics (IOVA), Urogen Pharma (URGN), Tilray Brands (TLRY), Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), Prime Medicine (PRME), Dianthus Therapeutics (DNTH), Phathom Pharmaceuticals (PHAT), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry.

Cybin vs. Its Competitors

Cybin (NYSE:CYBN) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Maravai LifeSciences had 6 more articles in the media than Cybin. MarketBeat recorded 6 mentions for Maravai LifeSciences and 0 mentions for Cybin. Cybin's average media sentiment score of 1.00 beat Maravai LifeSciences' score of 0.90 indicating that Cybin is being referred to more favorably in the media.

Company Overall Sentiment
Cybin Positive
Maravai LifeSciences Positive

Cybin presently has a consensus target price of $85.00, indicating a potential upside of 964.50%. Maravai LifeSciences has a consensus target price of $6.64, indicating a potential upside of 147.26%. Given Cybin's stronger consensus rating and higher possible upside, equities analysts plainly believe Cybin is more favorable than Maravai LifeSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cybin
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25
Maravai LifeSciences
1 Sell rating(s)
7 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.25

Cybin has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.

Cybin has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CybinN/AN/A-$57.88M-$3.88-2.06
Maravai LifeSciences$259.18M2.64-$144.85M-$1.14-2.36

17.9% of Cybin shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 2.1% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cybin has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -67.14%. Maravai LifeSciences' return on equity of -12.91% beat Cybin's return on equity.

Company Net Margins Return on Equity Return on Assets
CybinN/A -37.58% -36.59%
Maravai LifeSciences -67.14%-12.91%-6.87%

Summary

Cybin beats Maravai LifeSciences on 9 of the 16 factors compared between the two stocks.

Get Cybin News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYBN vs. The Competition

MetricCybinPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$188.37M$778.94M$5.72B$21.10B
Dividend YieldN/A4.84%4.60%3.58%
P/E Ratio-1.821.4028.0727.85
Price / SalesN/A26.98462.5860.47
Price / CashN/A19.5636.5523.00
Price / Book0.746.808.644.69
Net Income-$57.88M-$4.32M$3.24B$994.49M
7 Day Performance-4.03%1.28%4.08%1.57%
1 Month Performance-3.33%3.81%10.68%5.84%
1 Year PerformanceN/A8.20%34.47%11.42%

Cybin Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CYBN
Cybin
2.7079 of 5 stars
$7.97
-0.9%
$85.00
+966.5%
N/A$188.01MN/A-1.8250
MRVI
Maravai LifeSciences
3.6062 of 5 stars
$2.67
-2.2%
$6.64
+148.6%
-67.3%$679.94M$259.18M-2.34610Options Volume
IOVA
Iovance Biotherapeutics
4.6168 of 5 stars
$2.01
+7.5%
$12.22
+508.1%
-64.0%$671.20M$164.07M-1.62500Analyst Forecast
Options Volume
Gap Up
High Trading Volume
URGN
Urogen Pharma
4.5082 of 5 stars
$14.49
+1.8%
$32.86
+126.8%
+10.0%$668.13M$90.40M-4.56200
TLRY
Tilray Brands
1.8236 of 5 stars
$0.66
+13.1%
$1.92
+191.8%
-60.7%$661.07M$788.94M-0.632,650Upcoming Earnings
Options Volume
TNGX
Tango Therapeutics
1.6669 of 5 stars
$6.09
+2.7%
$12.20
+100.3%
-31.9%$660.12M$40.99M-4.9990
STOK
Stoke Therapeutics
4.2453 of 5 stars
$12.06
+1.7%
$24.75
+105.2%
-5.4%$658.48M$36.56M15.27100
PRME
Prime Medicine
3.853 of 5 stars
$4.80
+10.3%
$10.08
+110.1%
-20.8%$645.57M$3.85M-2.34234Gap Down
High Trading Volume
DNTH
Dianthus Therapeutics
1.3859 of 5 stars
$20.03
-0.1%
$53.00
+164.6%
-21.7%$644.17M$6.24M-6.9580Positive News
PHAT
Phathom Pharmaceuticals
4.31 of 5 stars
$9.06
-1.3%
$17.50
+93.2%
-21.0%$632.48M$55.25M-1.73110Positive News
UPB
Upstream Bio
1.7818 of 5 stars
$11.73
+2.2%
$56.50
+381.7%
N/A$631.00M$2.30M0.0038News Coverage

Related Companies and Tools


This page (NYSE:CYBN) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners